Quarterly ResultMay 7, 2026, 04:10 PM
10x Genomics Q1 Revenue $150.8M; Net Loss $13.5M
AI Summary
10x Genomics reported Q1 2026 revenue of $150.8 million, a 3% decrease year-over-year, though a 9% increase excluding one-time license revenue from Q1 2025. The company significantly reduced its net loss to $13.5 million from $34.4 million in the prior year period. Key highlights include the launch of the Atera platform for spatial whole-transcriptome analysis and a partnership with Bioptimus for the STELA spatial data generation initiative. The company maintained its full-year 2026 revenue guidance of $600 million to $625 million.
Key Highlights
- Launched Atera platform, expected to ship in H2 2026.
- Partnered with Bioptimus for STELA spatial data generation initiative.
- Q1 2026 Revenue: $150.8 million, a 3% decrease YoY (9% increase excluding one-time revenue).
- Q1 2026 Net Loss: $13.5 million, significantly reduced from $34.4 million loss in Q1 2025.
- Q1 2026 Gross Margin: 70%, an increase from 68% in the prior year period.
- Cash and cash equivalents: $539.8 million as of March 31, 2026.
- Full-year 2026 revenue guidance maintained at $600 million to $625 million.
- Total consumables revenue grew to $129.8 million from $115.4 million YoY.